Literature DB >> 2736800

Antigenic stimulation during ultraviolet therapy in man does not result in immunological tolerance.

P S Friedmann1, S I White, S Parker, C Moss, J N Matthews.   

Abstract

People receiving therapy with either 8-methoxypsoralen plus long wavelength ultraviolet radiation (PUVA) or medium wavelength ultraviolet radiation (UVB) have been studied to see whether their unresponsiveness to the contact sensitizer dinitrochlorobenzene (DNCB) is a form of immunological tolerance. It was confirmed that both PUVA and UVB therapy impair sensitization by DNCB:4/13 PUVA-treated and 9/29 UVB-treated psoriatic subjects became sensitized by a dose of DNCB which sensitizes 100% of untreated patients. Subjects unsuccessfully sensitized during PUVA therapy could subsequently be sensitized perfectly normally. Subjects unsuccessfully sensitized during UVB therapy showed slight impairment of subsequent sensitization which was not statistically significant, and which was probably a persistent effect of UVB exposure. In conclusion, the temporary unresponsiveness seen in human subjects exposed to antigens during PUVA or UVB therapy is not due to immunological tolerance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2736800      PMCID: PMC1541718     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  18 in total

1.  Effects of ultraviolet radiation on human epidermal cell alloantigen presentation: initial depression of Langerhans cell-dependent function is followed by the appearance of T6- Dr+ cells that enhance epidermal alloantigen presentation.

Authors:  K D Cooper; P Fox; G Neises; S I Katz
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

2.  Reappearance of epidermal Langerhans cells after PUVA therapy.

Authors:  P S Friedmann; G Ford; J Ross; B L Diffey
Journal:  Br J Dermatol       Date:  1983-09       Impact factor: 9.302

3.  Recovery of cutaneous immune responsiveness after PUVA therapy.

Authors:  S I White; P S Friedmann; C Moss; J M Simpson
Journal:  Br J Dermatol       Date:  1988-03       Impact factor: 9.302

4.  Quantitative relationships between sensitizing dose of DNCB and reactivity in normal subjects.

Authors:  P S Friedmann; C Moss; S Shuster; J M Simpson
Journal:  Clin Exp Immunol       Date:  1983-09       Impact factor: 4.330

5.  Effector and suppressor circuits of the immune response are activated in vivo by different mechanisms.

Authors:  H Okamoto; M L Kripke
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

6.  The effect of altering area of application and dose per unit area on sensitization by DNCB.

Authors:  S I White; P S Friedmann; C Moss; J M Simpson
Journal:  Br J Dermatol       Date:  1986-12       Impact factor: 9.302

7.  Disappearance of epidermal Langerhans cells during PUVA therapy.

Authors:  P S Friedmann
Journal:  Br J Dermatol       Date:  1981-08       Impact factor: 9.302

8.  Induction and regulation of contact hypersensitivity by resident, bone marrow-derived, dendritic epidermal cells: Langerhans cells and Thy-1+ epidermal cells.

Authors:  S Sullivan; P R Bergstresser; R E Tigelaar; J W Streilein
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

9.  Ultraviolet light depletes surface markers of Langerhans cells.

Authors:  W Aberer; G Schuler; G Stingl; H Hönigsmann; K Wolff
Journal:  J Invest Dermatol       Date:  1981-03       Impact factor: 8.551

10.  Analysis of the mechanism of unresponsiveness produced by haptens painted on skin exposed to low dose ultraviolet radiation.

Authors:  C A Elmets; P R Bergstresser; R E Tigelaar; P J Wood; J W Streilein
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

View more
  1 in total

1.  UV exposure reduces immunization rates and promotes tolerance to epicutaneous antigens in humans: relationship to dose, CD1a-DR+ epidermal macrophage induction, and Langerhans cell depletion.

Authors:  K D Cooper; L Oberhelman; T A Hamilton; O Baadsgaard; M Terhune; G LeVee; T Anderson; H Koren
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.